•  

Funding for Zucara Therapeutics Expansion Into ZT-01 Development Program to Type 2 Diabetes

November 2, 2020: Zucara Therapeutics Inc., a diabetes life sciences startup funded by TIAP and adMare BioInnovations,  announced today that it has received funding from NRC IRAP and MITAS for its expansion into the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”).

Red more here: https://bit.ly/34QRAn6